Evidence map›Paper›PMID 42622042›Full record

ReviewInternational journal of nanomedicine2026

ZIF-8 Nanodrug Delivery Systems: Construction Strategies, Functional Modifications, and Advances in Synergistic Tumor Therapy.

Rujia Xie, Wangxia Peng, Bozhi Zeng, Congcong Chen, Xinlei Tang, Hui Su, Kaixin Song, Xinhua Xia, Jing Yang

Abstract readReview
In one paragraph

Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rujia XieSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
Wangxia PengInstitute of Innovation and Applied Research in Chinese Medicine, Academy of Chinese Medical Sciences, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
Bozhi ZengSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
Congcong ChenSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
Xinlei TangSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
Hui SuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.
Kaixin SongSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.ORCID 0009-0009-2195-2127
Xinhua XiaSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.ORCID 0000-0003-2630-5585
Jing YangSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China.ORCID 0009-0005-2971-5725

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional chemotherapeutic agents are commonly hampered by off-target toxicity and multidrug resistance. Although nanoscale delivery systems can enhance targeting and controlled release, they are frequently constrained by insufficient drug-loading capacity. Zeolitic imidazolate framework-8 (ZIF-8), a metal-organic framework self-assembled from Zn

Indexed as

Antineoplastic AgentsDrug Delivery SystemsImidazolesMetal-Organic FrameworksNanoparticle Drug Delivery SystemNeoplasmsZeolitesAnimalsCombined Modality TherapyHumansNanomedicineAntineoplastic AgentsImidazolesMetal-Organic FrameworksNanoparticle Drug Delivery SystemZeolitesZIF-8 metal-organic frameworkdrug deliverymetal-organic frameworkspH-responsivesynergistic therapytumor therapyZIF-8

Identifiers

PMID42622042
PMCPMC13489057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.